Clinical trials: Immunocompromised Patients
Fungal Infection
Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)
This is an open-label study of MK0991 in children between 3 to 24 months of age with new onset fever and neutropenia. The purpose of the study is to investigate plasma drug levels of caspofungin.
- Trial name
- NCT00292071
- Testing
- caspofungin acetate
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Fungal Infections
A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)
The purpose of this dose-escalation study is to evaluate the pharmacokinetics, safety, and tolerability of oral posaconazole in immunocompromised children with neutropenia or expected neutropenia.
- Trial name
- NCT01716234
- Testing
- Posaconazole 12 mg/kg/day BID, Posaconazole 18 mg/kg/day BID, Posaconazole 18 mg/kg/day TID
- Volunteers
- 142 people
- Sponsor
- Merck Sharp & Dohme LLC
Persistent COVID-19, B Cell Malignancies
Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients
Spontaneous international multicenter retrospective and prospective observational study which objective is to evaluate the prevalence and risk factors of persistent SARS-CoV-2 infection within a population of hematology patients…
- Trial name
- PERsiCO (NCT06576102)
- Testing
- Persisting SARS-CoV-2 infection
- Where
- 5 sites in Italy, Spain
- Volunteers
- 204 people
- Sponsor
- Maddalena Giannella
Chronic Pulmonary Aspergillosis
Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole
This study compares the therapeutic (clinical and radiological) efficacy of a six-month treatment by itraconazole and nebulised Ambisome® (liposomal amphotericin B = LAmB) versus treatment by itraconazole alone, in non - or…
- Trial name
- NCT03656081
- Testing
- inhaled Ambisome®, Itraconazole
- Where
- France
- Volunteers
- 224 people
- Sponsor
- Poitiers University Hospital
Hematologic Disease, Neoplams
Retrospective Non-interventional Analysis of Opportunistic Infections in Immunocompromised and Frail Patients
The analysis of a cohort of consecutive non-selected patients from the Strasbourg University Hospital, and therefore representative of the real life, will allow better identifying the risk factors for these infections (by…
- Conditions
- Hematologic Disease, Neoplams, Transplantation, Immunologic Deficiency Syndromes
- Trial name
- NCT03920735
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Strasbourg, France
Kidney Transplantation, Immunity
Mucosal Response in Immunocompromised Host
The aim of this study is to verify whether vaccination with Dukoral® (SBL Vaccines) induces an immune response in renal transplant recipients on prednisolone in combination with either a calcineurin inhibitor CNI) or…
- Trial name
- MICH (NCT01109914)
- Testing
- Dukoral
- Where
- Netherlands
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Tuberculosis
Tuberculosis (TB) Screening for the Diagnosis of Latent TB in Immunocompromised Populations
The tuberculin skin test (TST) has been the gold standard for diagnosing latent tuberculosis for almost 100 years. While this test performs reasonably well in healthy, non-bacille Calmette-Guerin (BCG) vaccinated populations, it…
- Trial name
- NCT00134342
- Testing
- T-SPOT TB ELISPOT test
- Where
- 2 sites in Canada
- Volunteers
- 203 people
- Sponsor
- University Health Network, Toronto
Malignancy, Allogeneic Stem Cell Transplantation
Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)
The purpose of this study is to evaluate the efficacy of levofloxacin to prevent bacterial infections in the postneutropenic period in patients who have undergone allogeneic stem cell transplantation (SCT).
- Trial name
- NCT00215007
- Testing
- Levofloxacin
- Where
- Germany
- Sponsor
- Charite University, Berlin, Germany
Severe Acute Respiratory Infection, Community-acquired Pneumonia
mNGS -Guided Antimicrobial Treatment in Early Severe Community-Acquired Pneumonia Among Immunocompromised Patients
Severe Community-acquired pneumonia (SCAP) is a leading global infectious cause of intensive care unit (ICU) admission (approximately 20%-30%), and the primary reason of mortality and morbidity in immunocompromised patients.
- Conditions
- Severe Acute Respiratory Infection, Community-acquired Pneumonia, Respiratory Tract Infections, Pneumonia
- Trial name
- MATESHIP (NCT05290454)
- Testing
- mNGS-guided treatment
- Where
- China
- Volunteers
- 342 people
- Sponsor
- Qilu Hospital of Shandong University
Antimicrobial Drug Resistance, Antibiotic Resistant Infection
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
The goal of this observational study is to investigate how bacterial populations from the intestine and mouth of patients change during the hospitalization period and evaluate if some populations of specific bacteria increase or…
- Conditions
- Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection
- Trial name
- DYNAMITE (NCT06258551)
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Rheumatologic Disorder, Inflammatory Bowel Diseases
Flu Vaccine Response in Patients on Biologic Therapies
This proposed study will assess the immunogenicity, safety, and clinical efficacy of an influenza vaccine booster dose strategy in patients with autoimmune diseases who are receiving immunosuppressive therapies.
- Conditions
- Rheumatologic Disorder, Inflammatory Bowel Diseases, Immune Complex Diseases
- Trial name
- NCT03277703
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stony Brook University
Herpes Zoster
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)
This is a randomized, double-blind, placebo-controlled study to assess the safety and tolerability of V212 when administered to adults with solid tumor malignancy (STM) receiving chemotherapy and to assess the impact of V212 on…
- Trial name
- NCT01254630
- Testing
- V212
- Volunteers
- 5,305 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19, Immunodeficiency
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients
The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy direct antiviral agents (remdesivir + nirmatrelvir/r) versus the reference monotherapy (nirmatrelvir/r alone) and…
- Trial name
- SWISS OPTICOV (NCT07406217)
- Testing
- Paxlovid 5 days, Paxlovid 10 days
- Where
- 4 sites in Switzerland
- Volunteers
- 256 people
- Sponsor
- Calmy Alexandra
Emerging Infectious Diseases and Their Treatments
Biological Collection on Emerging Infectious Diseases and Their Treatments
Unprecedented changes in human-environment interactions and increasing disruptions to ecosystems and the climate have contributed to the emergence of infectious diseases (Emerging Infectious Diseases, EIDs).
- Trial name
- COMETE (NCT07674550)
- Where
- France
- Volunteers
- 5,300 people
- Sponsor
- University Hospital, Toulouse
Pneumocystis, Immunocompromised Patients
Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients
Evaluate new diagnostic methods using qPCR on non-invasive samples, compared with reference techniques for the positive diagnosis of pneumocystis (PcP) in immunocompromised patients
- Trial name
- OPTIJIROVEC (NCT06890078)
- Testing
- Biological sampling
- Where
- 4 sites in France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Aspergillosis
To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early
Chemotherapy lowers the white blood cell count or weakens the immune system for a long time. This puts the patients at a high risk of getting a serious fungal infection of the internal organs or blood.
- Trial name
- NCT00361517
- Testing
- Galactomannan antigen monitoring, Aspergillus PCR, blood draws, blood draws for GM monitoring
- Where
- Singapore
- Volunteers
- 47 people
- Sponsor
- Singapore General Hospital
Fever, Mycoses
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
The objective of this study is to evaluate the safety, tolerance, and pharmacokinetics of FK463, a novel echinocandin (cell wall-active antifungal lipopeptide), as early empirical therapy for prevention of fungal infections in…
- Conditions
- Fever, Mycoses, Neutropenia
- Trial name
- NCT00001790
- Testing
- FK463
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Herpes Zoster, Immunologic Deficiency Syndromes
Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster
OBJECTIVES: I. Compare the efficacy and safety of two doses of oral valacyclovir in immunocompromised patients with uncomplicated herpes zoster. II.
- Trial name
- NCT00006131
- Testing
- Valacyclovir
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Center for Research Resources (NCRR)
Immunocompromised Patients, SARS-CoV-2 Disease
Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19.
Due to the lower virulence of circulating Omicron variants and the high seroprevalence of anti-SARS-CoV-2 antibodies, the incidence of cases and deaths related to the SARS-CoV-2 virus has significantly decreased in recent months…
- Trial name
- COV-ID (NCT06683937)
- Testing
- Collection of data from the patient's medical file
- Where
- 18 sites in France
- Volunteers
- 327 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Candidiasis, Esophageal, HIV Infections
A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
To compare the safety, tolerance, and effectiveness of fluconazole and ketoconazole in the treatment of candidal esophagitis in immunocompromised patients.
- Trial name
- NCT00002304
- Testing
- Ketoconazole, Fluconazole
- Where
- 42 sites in United States, Canada
- Sponsor
- Pfizer